Innate Pharma will speed up the development of its anti-KIR3DL2 antibody IPH4102, to treat T-cell lymphoma, as it has been fast tracked by the US FDA, the company said Tuesday.
Pierre Dodion, Chief Medical Officer of Innate Pharma, said that IPH4102 is a key element of Innate’s strategy to build a commercial franchise of treatments focused on rare cancers in the field of hemato-oncology.
The company plans to start a global multi-cohort Phase II study (Tellomak) in the first half of 2019 to confirm the ability of IPH4102 in Sézary syndrome and to test its potential in other subtypes of T-cell lymphomas, including Mycosis fungoides (MF), as well as peripheral T-cell lymphoma (PTCL).
Before Fast-Track Designation, IPH4102 was granted orphan drug status in the European Union and in the United States for the treatment of Cutaneous T-Cell Lymphoma .
Sézary syndrome is the leukemic variant of cutaneous T-cell lymphoma (CTCL), a heterogeneous group of non-Hodgkin’s lymphomas which arise primarily in the skin. Patients often experience very poor quality of life with severe and debilitating pruritus (chronic itchy skin). Despite recent advancements, Sézary syndrome is associated with a high relapse rate with currently available therapies.
By Dino Mustafić